AKBA
Akebia Therapeutics, Inc.
0.98$
+4.4%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -100.0% | – | +11,495.0% | +16.7% | +61.3% | -11.8% | -27.7% | +36.9% | -33.5% | -17.7% | +47.5% | |
| – | -99.6% | +120,509.4% | -99.5% | +1,145.5% | +1,791.2% | +103.6% | -48.2% | -85.3% | +229.6% | -14.8% | -37.5% | |
| – | – | – | – | +12.8% | -5.2% | -100.3% | – | +348.6% | -55.4% | -19.5% | +102.8% | |
| – | +69.4% | +169.2% | +99.4% | +26.1% | +11.0% | -32.4% | -32.3% | +12.3% | -62.0% | -40.3% | +65.6% | |
| – | +47.5% | +20.1% | +21.6% | +222.6% | +75.6% | +2.9% | +12.9% | -25.8% | -97.5% | +3,049.4% | +5.4% | |
| – | +62.1% | +124.3% | +86.9% | +46.6% | +25.8% | -21.0% | -13.4% | +7.8% | -52.5% | -11.5% | +17.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +147.6% | +76.7% | +210.7% | +119.9% | +527.9% | -77.0% | +124.7% | -21.3% | -61.5% | +201.5% | +33.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | +209.9% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -370.5% | – | – |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.